779 related articles for article (PubMed ID: 27533061)
1. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
6. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
7. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
8. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A; Catapano AL
Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
[TBL] [Abstract][Full Text] [Related]
10. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
13. The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors.
Nicholls SJ
Curr Cardiol Rep; 2019 Mar; 21(4):18. PubMed ID: 30828741
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
15. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
[TBL] [Abstract][Full Text] [Related]
16. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T
J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
[TBL] [Abstract][Full Text] [Related]
17. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
19. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
20. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Taylor BA; Thompson PD
Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
